Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3

Sun,Miaonan; Tang,Huichun; Gao,Yan; Dai,Xinxuan; Yuan,Yue; Zhang,Chunmei; Sun,Dejun

doi:10.3892/or.2016.4570

Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3

Authors:
- Miaonan Sun
- Huichun Tang
- Yan Gao
- Xinxuan Dai
- Yue Yuan
- Chunmei Zhang
- Dejun Sun
View Affiliations

Affiliations: Department of Biomedicine, Regeneration Medicine Institute, Jilin University, Changchun, Jilin 130061, P.R. China, Jilin Zixin Pharmaceutical Co., Ltd., Changchun, Jilin 130041, P.R. China
Published online on: January 18, 2016 https://doi.org/10.3892/or.2016.4570
Pages: 1987-1994

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Onconase is an RNase of the ribonuclease A superfamily that is purified from the Northern leopard frog (Rana pipiens). It targets several types of malignant tumors, digests cytoplasmic transfer RNA (tRNA), and causes tumor cell apoptosis. Onconase has been employed in clinical trials as an antitumor drug, and has revealed its valuable clinical activity in several types of tumors, particularly pleural mesothelioma. However, its inefficiency in targeting tumor cells and its non‑specific toxicity in normal tissues have diminished its clinical benefits. Furthermore, cyclization of the N-terminal glutamine residue (Gln), possesses more RNase activity than the structure of Met ahead of Glu in the N-terminal (99:1), which is more difficult for producing onconase by Pichia pastoris. Under the guidance of α-mating factor-pre (α-MF-pre) secretion signal, the secretion of the recombinant protein can reach a high level. In the present study, we constructed a constitutive expression vector for onconase-(DV3)2 (Onc-DV3) production in yeast Pichia pastoris with the GAP promoter, in which the Onc-DV3 gene is inserted downstream of the truncated Saccharomyces cerevisiae α-mating factor-pre (α-MF-pre) secretion signal. The immuno-RNase Onc-DV3 expressed a high level of production and bioactivity and possessed enhanced capability to deliver the Onc molecule to tumor cell monomeric counterparts. Notably, Onc-DV3 showed strong cytotoxicity to highly metastatic tumor cells, weak cytotoxicity to lowly metastatic tumor cells and no toxicity to normal cells. These results demonstrate that the specific toxicity to highly metastatic tumor cells has made Onc-DV3 a promising antitumor drug by using two copies of DV3 for the targeted delivery of onconase.

View Figures

View References

1	Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinet. 21:169–182. 1988.PubMed/NCBI
2	Mosimann SC, Ardelt W and James MN: Refined 1.7 A X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol. 236:1141–1153. 1994. View Article : Google Scholar : PubMed/NCBI
3	Ardelt W, Mikulski SM and Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem. 266:245–251. 1991.PubMed/NCBI
4	Gorbatyuk VY, Tsai CK, Chang CF and Huang TH: Effect of N-terminal and Met23 mutations on the structure and dynamics of onconase. J Biol Chem. 279:5772–5780. 2004. View Article : Google Scholar
5	Bretscher LE, Abel RL and Raines RT: A ribonuclease A variant with low catalytic activity but high cytotoxicity. J Biol Chem. 275:9893–9896. 2000. View Article : Google Scholar : PubMed/NCBI
6	Wu Y, Mikulski SM, Ardelt W, Rybak SM and Youle RJ: A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem. 268:10686–10693. 1993.PubMed/NCBI
7	Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K and Youle RJ: Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem. 277:15142–15146. 2002. View Article : Google Scholar : PubMed/NCBI
8	Suhasini AN and Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 281:12201–12209. 2006. View Article : Google Scholar : PubMed/NCBI
9	Rodríguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF, Ribó M, Benito A, Vilanova M and Beaumelle B: Intracellular pathway of onconase that enables its delivery to the cytosol. J Cell Sci. 120:1405–1411. 2007. View Article : Google Scholar : PubMed/NCBI
10	Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM and Rybak SM: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood. 97:528–535. 2001. View Article : Google Scholar : PubMed/NCBI
11	Pavlakis N and Vogelzang NJ: Ranpirnase - an antitumour ribonuclease: Its potential role in malignant mesothelioma. Expert Opin Biol Ther. 6:391–399. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lee I, Kalota A, Gewirtz AM and Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 27:299–307. 2007.PubMed/NCBI
13	Chang CH, Gupta P, Michel R, Loo M, Wang Y, Cardillo TM and Goldenberg DM: Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther. 9:2276–2286. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hu XF and Xing PX: Discovery and validation of new molecular targets for ovarian cancer. Curr Opin Mol Ther. 5:625–630. 2003.
15	Ménard S, Pupa SM, Campiglio M and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 22:6570–6578. 2003. View Article : Google Scholar : PubMed/NCBI
16	Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
17	Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM and Dowdy SF: Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res. 65:10646–10650. 2005. View Article : Google Scholar : PubMed/NCBI
18	Saar K, Lindgren M, Hansen M, Eiríksdóttir E, Jiang Y, Rosenthal-Aizman K, Sassian M and Langel U: Cell-penetrating peptides: A comparative membrane toxicity study. Anal Biochem. 345:55–65. 2005. View Article : Google Scholar : PubMed/NCBI
19	Lu S, Tager LA, Chitale S and Riley LW: A cell-penetrating peptide derived from mammalian cell uptake protein of Mycobacterium tuberculosis. Anal Biochem. 353:7–14. 2006. View Article : Google Scholar : PubMed/NCBI
20	Snyder EL and Dowdy SF: Cell penetrating peptides in drug delivery. Pharm Res. 21:389–393. 2004. View Article : Google Scholar : PubMed/NCBI
21	Rhee M and Davis P: Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J Biol Chem. 281:1233–1240. 2006. View Article : Google Scholar
22	Watkins CL, Brennan P, Fegan C, Takayama K, Nakase I, Futaki S and Jones AT: Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Control Release. 140:237–244. 2009. View Article : Google Scholar : PubMed/NCBI
23	Park JW, Bang EK, Jeon EM and Kim BH: Complexation and conjugation approaches to evaluate siRNA delivery using cationic, hydrophobic and amphiphilic peptides. Org Biomol Chem. 10:96–102. 2012. View Article : Google Scholar
24	Macauley-Patrick S, Fazenda ML, McNeil B and Harvey LM: Heterologous protein production using the Pichia pastoris expression system. Yeast. 22:249–270. 2005. View Article : Google Scholar : PubMed/NCBI
25	Damasceno LM, Huang CJ and Batt CA: Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol. 93:31–39. 2012. View Article : Google Scholar
26	Sinha J, Plantz BA, Inan M and Meagher MM: Causes of proteolytic degradation of secreted recombinant proteins produced in methylotrophic yeast Pichia pastoris: Case study with recombinant ovine interferontau. Biotechnol Bioeng. 89:102–112. 2005. View Article : Google Scholar
27	Vassileva A, Chugh DA, Swaminathan S and Khanna N: Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. J Biotechnol. 88:21–35. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Sun Y, Ke F, Zhao H, Liu T, Xu L, Liu Y and Yan Y: Constitutive expression of yarrowia lipolytica lipase LIP2 in Pichia pastoris using GAP as promoter. Appl Biochem Biotechnol. 166:1355–1367. 2012. View Article : Google Scholar : PubMed/NCBI
29	Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS and Kragh M: Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 70:588–597. 2010. View Article : Google Scholar : PubMed/NCBI
30	Wang Q, Villeneuve G and Wang Z: Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 6:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
31	Fan Z, Lu Y, Wu X and Mendelsohn J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 269:27595–27602. 1994.PubMed/NCBI
32	Perez-Torres M, Guix M, Gonzalez A and Arteaga CL: Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem. 281:40183–40192. 2006. View Article : Google Scholar : PubMed/NCBI
33	Vasandani VM, Burris JA and Sung C: Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother Pharmacol. 44:164–169. 1999. View Article : Google Scholar : PubMed/NCBI
34	Mikulski S, Grossman A, Carter P, Shogen K and Costanzi J: Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors. Int J Oncol. 3:57–64. 1993.PubMed/NCBI
35	Vasandani VM, Wu YN, Mikulski SM, Youle RJ and Sung C: Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily. Cancer Res. 56:4180–4186. 1996.PubMed/NCBI